Abstract
Aim: To determine serum homocysteine concentration in type 2 diabetes patients with chronic coronary syndrome (CCS) and to explore the relationship between homocysteine concentrations and some clinical and paraclinical characteristics of the above patients group.
Background: Homocysteine (Hcy) - a sulfur-containing amino acid - is a product of the methionine reduction process and is related to the formation of atherosclerotic plaque through the mechanism of increasing oxidative stress, coagulation, thickening the smooth muscle of arterial wall, and disrupting the endothelium of blood vessels.1 Therefore, increased blood homocysteine is considered an independent risk factor for coronary artery disease.
Subject and method: type 2 diabetes inpatients with chronic coronary syndrome who treated at the National Endocrinology Hospital from January 2023 to October 2023.
Method: Descriptive and cross-sectional study.
Results: 53 patients (27 men, 26 women, mean age 72.4 ± 8.6) were eligible to participate in the study. We found:
- The average serum homocysteine concentration in type 2 diabetes patients with chronic coronary syndrome is 14.95 ± 5.01 µmol/L and 54.7% of them have serum Hcy concentration > 15 µmol/L.
- The average serum homocysteine concentration in group of type 2 diabetes patients with chronic coronary syndrome and chronic kidney disease (eGFR < 60 ml/min) is 16,3 ± 4,6 µmol/L, higher than the group patients without chronic kidney disease (13,3 ± 5,1 µmol/L), and 2,98 times higher (r = 2,98; 95%CI: 0,3 – 5,7) with statistical significance with p < 0,05.
- The average serum homocysteine concentration in group of type 2 diabetes patients with chronic coronary syndrome and a history of stroke (18,3 ± 3,0 µmol/L) was higher than the group patients without history of stroke (14,3 ± 5,1 µmol/L), and 4,07 times higher (r = 4,07; 95%CI: 0,5 – 7,6) with statistical significance with p < 0,05.
- The average serum homocysteine concentration in group of type 2 diabetes patients with chronic coronary syndrome and peripheral arterial diseases (carotid artery, lower extremity artery) (18,1 ± 2,6 µmol/L) was higher than the group patients without peripheral arterial diseases (13,5 ± 5,2 µmol/L), and 4,67 times higher (r = 4,67; 95%CI: 2,0 – 7,4) with statistical significance with p < 0,05.
Conclusion: Serum homocysteine concentration in type 2 diabetic patients with chronic coronary syndrome in the study is 14.95 ± 5.01 µmol/L with the rate of hyperhomocysteinemia > 15 µmol/L being 54.7%. And serum homocysteine concentrations increased in study groups with chronic kidney disease, history of stroke, and peripheral aterial diseases.